Skip to main content

Use of 'Benzo' Sedatives Like Valium, Xanax Won't Raise Dementia Risk: Study

Medically reviewed by Carmen Pope, BPharm. Last updated on July 2, 2024.

By Dennis Thompson HealthDay Reporter

TUESDAY, July 2, 2024 -- Benzodiazepines do not appear to increase dementia risk, but could have subtle long-term effects on brain structure, a new study reports.

Researchers found no link between use of the sedative drug and a higher risk of dementia in a group of more than 5,400 adults in the Netherlands, according to findings published July 2 in the journal BMC Medicine.

That runs counter to two previous meta-analyses reporting increased dementia risk with benzodiazepine use, researchers noted.

However, brain MRI scans taken of more than 4,800 participants revealed that benzodiazepine use is associated with accelerated shrinking of some brain regions, results show.

The findings “support current guidelines cautioning against long-term benzodiazepine prescription,” concluded the research team led by Dr. Frank Wolters, a senior scientist of epidemiology and radiology and nuclear medicine at Erasmus Medical Center in the Netherlands.

“Further research is needed to investigate the potential effects of benzodiazepine use on brain health,” the team adds.

Benzodiazepines promote the release of a neurotransmitter that makes the nervous system less active, the Cleveland Clinic says. Different types are used as sedatives or to treat anxiety, insomnia and seizures.

Analysis of medical records between 2005 and 2020 and pharmacy records between 1991 and 2008 revealed no association between benzodiazepines and increased risk of dementia, regardless of the total quantity of sedatives people took over time.

The team also found no link between dementia risk and specific types of benzodiazepines or the time it took for dosages to wear off.

However, benzodiazepine use was associated with an accelerated reduction in the volume of the hippocampus and amygdala, which are brain regions involved in memory and mood regulation.

Certain types of benzodiazepines also were associated with changes in the size of white matter, which transmits nerve signals between brain regions, researchers said.

Anxiolytic benzodiazepines prescribed for anxiety caused less shrinkage of white matter, results show. These include alprazolam (Xanax), clonazepam (Klonopin), clorazepate (Tranxene) and lorazepam (Ativan, Loreev), according to the Cleveland Clinic.

On the other hand, sedative-hypnotic benzodiazepines prescribed for sleep problems caused a quicker reduction in white matter volume. These include temazepam (Restoril), triazolam (Halcion) and quazepam (Doral), the Cleveland Clinic says.

Sources

  • Erasmus Medical Center, news release, June 2, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Early Menopause Might Mean Greater Age-Related Brain Decline

WEDNESDAY, April 23, 2025 -- Early menopause could be a warning sign for future age-related brain decline, a new study says. Women who entered menopause before 40 had a greater...

Heavy Weed Use Increases Risk Of Dementia

WEDNESDAY, April 16, 2025 -- Middle-aged folks and seniors whose weed use lands them in the hospital are at higher risk for developing dementia within a matter of years, a new...

Everyday Digital Tech Is Protecting Seniors' Brain Health, Study Says

TUESDAY, April 15, 2025 -- It’s a common notion that overuse of smartphones, tablets, laptops and other digital devices is rotting people’s minds. But the opposite...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.